今年以来,云南省积极开展拥有自主知识产权的重大新产品研究开发工作。到目前为止,预防用生物制品6类新药Ⅰ型+Ⅲ型口服脊髓灰质炎减毒活疫苗(人二倍体细胞)及Ⅰ型+Ⅲ型脊髓灰质炎减毒活疫苗糖丸(人二倍体细胞)均已于2014年5月获得国家食品药品监督管理局颁发的《药品临床注册批件》,准备启动其临床试验研究。 Since the beginning of this year, Yunnan Province has actively carried out major new product research and development with independent intellectual property rights. To date, six types of live attenuated vaccine against human immunodeficiency virus type I and type III (human diploid cells) and type I + III poliovirus vaccine Somatic cells) were approved by the State Food and Drug Administration in May 2014, “drug clinical registration approval document,” ready to start its clinical trial study.